Nan Fung Life Sciences and affiliate Pivotal BioVenture Partners invested in the ophthalmology therapy developer having incubated it last year.
China-based ophthalmology startup Arctic Vision received $32m in series A funding from investors including Nan Fung Life Sciences, a subsidiary of property development group Nan Fung, yesterday.
Venture capital firm Morningside Venture Capital led the round, which also featured Pivotal BioVenture Partners, the healthcare investment firm co-founded by Nan Fung Life Sciences.
Arctic Vision’s lead product candidate is ARVN001, a potential treatment for a version of macular edema – a condition where fluid accumulates in the centre of the retina…
